Dementia Care and Caregiver Support Intervention Research - Stage I Only
ID: 359867Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359867
Timeline
    Description

    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "Dementia Care and Caregiver Support Intervention Research - Stage I Only," aimed at supporting research focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative will utilize the R34 activity code and is designed to facilitate the development, modification, and refinement of principle-based behavioral interventions, ensuring their acceptability and feasibility in preparation for later-stage clinical trials. Interested small businesses are encouraged to begin forming collaborations and developing project proposals, with the estimated synopsis posting date on November 1, 2025, and a closing date for applications expected by February 16, 2026. For further inquiries, potential applicants can contact Melissa Riddle, Ph.D., at melissa-riddle@nih.gov or by phone at 301-480-6761.

    Point(s) of Contact
    Melissa Riddle, Ph.D. National Institute on Aging (NIA)
    (301) 480-6761
    melissa-riddle@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Dementia Care and Caregiver Support Intervention Research - Stages II - V
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for research applications focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative aims to support a milestone-driven planning phase lasting up to two years, with the potential for transition to a clinical trial phase upon successful completion of the required milestones. The funding opportunity is particularly significant as it addresses critical health challenges associated with aging and dementia care. Interested small businesses are encouraged to prepare for this opportunity, with the estimated synopsis posting date set for November 1, 2025, and applications expected to close by February 16, 2026. For further inquiries, potential applicants can contact Dr. Melissa Riddle at melissa-riddle@nih.gov or by phone at 301-480-6761.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    National Alzheimer’s Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the establishment of a National Alzheimer's Coordinating Center (NACC) under a cooperative agreement. The NACC aims to serve as a national data resource for Alzheimer's disease and related dementias (AD/ADRD) research, facilitating data collection from Alzheimer’s Disease Research Centers (ADRCs) and enhancing communication within the ADRC program. This initiative is crucial for advancing research in the field of aging and dementia, providing a centralized hub for collaboration and data sharing. Interested small businesses are encouraged to prepare for the application process, with the estimated synopsis posting date on August 15, 2025, and the anticipated award date set for July 15, 2026. For further inquiries, potential applicants can contact Dr. Cerise Elliott at elliottce@nih.gov or by phone at 301-496-9350.
    Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer's Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer's disease (AD) and related dementias (ADRD). This initiative seeks to foster collaborative efforts between applicants, the National Institute on Aging (NIA), and the ACTC network to test promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat symptoms associated with AD and ADRD. The funding opportunity, utilizing the R01 activity code, is particularly significant as it addresses the growing need for effective treatments for age-related cognitive decline. Interested small businesses are encouraged to prepare for application submission, with the estimated synopsis post date on August 1, 2025, and a closing date of October 5, 2025. For further inquiries, potential applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease Risk
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's and Related Dementias Disease Risk." This initiative aims to foster research that integrates epidemiologic, genomic, and mechanistic studies to uncover the molecular and cellular determinants of resilience against Alzheimer's disease (AD) and related dementias (ADRD) through data-driven, systems-based approaches, including artificial intelligence and machine learning. The program is particularly significant as it seeks to generate high-dimensional molecular data from brain and peripheral tissues, facilitating the discovery of molecular predictors of resilience across diverse populations. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the opportunity, which is expected to utilize the U01 activity code. For further inquiries, potential applicants can contact Dr. Suzana Petanceska at petanceskas@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is February 26, 2026, with a projected award date of April 5, 2027.